Pemphigus Vulgaris pathophysiology in children
Pemphigus vulgaris (PV) is primarily recognized as an autoimmune blistering disorder predominantly affecting adults, but its occurrence in children, though rare, presents unique challenges in understanding its pathophysiology. The disease is characterized by the production of autoantibodies directed against desmosomal proteins, which are crucial components of cell-to-cell adhesion within the epidermis. These autoantibodies mainly target desmoglein 3, and in some cases, desmoglein 1, disrupting the integrity of the skin and mucous membranes.
In children, the pathophysiology of PV involves an abnormal immune response where the immune system mistakenly recognizes desmogleins as foreign antigens. Normally, desmogleins serve as adhesion molecules that maintain the cohesion of keratinocytes—the predominant cell type in the epidermis. When autoantibodies bind to these proteins, they impair cell adhesion, leading to acantholysis, the process where keratinocytes lose their connections. This loss of cohesion results in intraepidermal blister formation, which is characteristic of pemphigus vulgaris.
The immune dysregulation underlying PV in children is complex and not fully understood, but it involves both genetic and environmental factors. Certain HLA gene alleles are associated with increased susceptibility, suggesting a genetic predisposition. Environmental triggers such as infections or drugs may initiate or exacerbate the autoimmune response. The production of pathogenic IgG autoantibodies against desmogleins is central to disease development. These antibodies can activate complement pathways and recruit inflammatory cells like eosinophils and neutrophils, further contributing to tissue damage.
The pathogenic autoantibodies interfere with desmoglein-mediated adhesion, causing basal keratinocytes to detach from each other, leading to the formation of fragile blisters. Interestingly, the levels of circulating autoantibodies often correlate with disease activity, making them useful both diagnostically and as markers for monitoring treatment response. In children, the presentation can be more variable than in adults, sometimes involving extensive mucosal lesions, skin erosions, or a combination of both.
The inflammatory response also plays a role in perpetuating tissue damage. Cytokines released by immune cells amplify the process, promoting further autoantibody production and tissue destruction. The disruption of skin integrity predisposes children to secondary infections, complicating the disease course. Managing PV in pediatric patients requires addressing both the autoimmune process and the inflammatory cascade, often involving immunosuppressive therapies like corticosteroids, along with other steroid-sparing agents.
Understanding the pathophysiology of pemphigus vulgaris in children underscores the importance of early diagnosis and targeted treatment. While the autoimmune mechanisms are complex, advancements in immunology and molecular biology continue to shed light on potential therapeutic targets, aiming to reduce autoantibody production and restore normal cell adhesion, ultimately improving outcomes for affected children.